Our Ecosystem

Dr. Gene Weinstein is a board-certified diagnostic neuroradiologist at Mass General Brigham, specializing in advanced brain, spine, and head and neck imaging. A respected clinician, educator, and consultant, Dr. Weinstein brings more than a decade of expertise for one of the nation's leading academic medical centers. His work spans tertiary referral centers, multidisciplinary neurologic programs, and 

cross-functional care teams supporting both acute and longitudinal patient management.

Beyond academia, Dr Weinstein is the founder of Weinstein Consulting, providing neuroradiology expertise and expert-witness consultation in personal injury and medical malpractice cases.

His background in teaching and- medicolegal communication allows him to bridge technical rigor with clarity and accessibility.

Dr Weinstein is deeply aligned with Synera's mission of pairing clinician expertise with operational commercialization support. 

 He brings a multidimensional perspective across deep clinician perspective, rigorous evidence-based practice and consulting engagements in clinical and academic domains that strengthen Synera's physician-led approach.

Jonathan Chasper is a transformative technology and product leader with over twenty years of architecting category defining platforms, scaling global engineering organizations, and accelerating enterprise growth access SaaS, AI, digital health, and deep tech. 

A founder, operator, and visionary strategist, Jonathan has guided companies from concept to commercialization, launched more than 20 enterprise platforms, and shaped product ecosystems that support millions of users.

As CEO of Product Savvy and a former CTO/CPTO, Jonathan has led high-performance engineering and product teams internationally. Hisl leadership consistently delivers measurable outcomes including more than $40M in capital rasies. Jonathan excels at aligning technology, business imperatives, and product execution to create scalable, durable market advantage.

Jonathan's approach blends hands-on engineering depth with strategic  foresight, commercial rigor, and a belief in purposeful innovation. He is known for building cultures defined by autonomy, transparency, and accountability-enabling organizations to move faster, think smarter, and execute with discipline. His role as mentor, advisor, and author reflects a long-standing commitment to developing leaders and elevating the next generation of founders to product executives.

Jonathan's strategic partnership with Synera Advisory strengthens the firm's ability to drive founder-led product strategy, enterprise platform design, commercial readiness, and technology enabled scale. His cross-sector perspective-spanning digital health, aerospace, and enterprise SaaS-supports Synera clients in navigating platform architecture, AI integration, product roadmap strategy, and technical due diligence with unmatched clarity.

Jonathan works with leadership teams who are building what is next, organizations seeking to accelerate innovation, crystallize product vision, and unlock scalable growth.

Craig Coombs is a seasoned regulatory strategist and commercialization advisor with more than three decades of leadership driving FDA-aligned product development and market entry for medical devices, digital health, and AI-enabled clinical technologies. As a senor strategic partner with Synera Advisory, Craig amplifies our capability to advance early-stage innovations with robust regulatory design, practical execution frameworks, and investor-ready submission strategies. 

As part of Synera's integrated commercialization platform, he identifies optimal FDA pathways and predicate strategy, Craig helps founders align product design and evidence plans to both clinical and commercial milestones. Craig integrates regulatory planning with real-world reimburrsement and clinical adoption frameworks ensuring that pathway decisions support scalable revenue potential. Craig's pragmatic regulatory intelligence strengthens diligence packages, supports board-level discussions, and enhances investor confidence by translating complex requirements into clear risk-adjusted decisions.

Craig combines rigorous regulatory judgement with real-world execution experience. His ability to clarity the FDA landscape and link it directly to clinical and commercial outcomes accelerate progress and mitigates risk for emerging Ahealth technologies. In partnership with Snyera Advisory's physician-led commercialization model, Craig reinforces our commitment to operational excellence, evidence-based strategy, and breakthrough innovation.

David Pudwill is a seasoned leader and regulatory expert who helps companies get medical devices and combination products to market.

David has served in senior leadership roles at AscentX Medical and ConvaTec, and previously worked at the U.S. Food and Drug Administration (FDA), and St. Jude Medical. He is a founding member of the Kidney Health Initiative, and has helped several startups acquire funding and successfully interact with FDA and the Department of Defense. While at FDA, David was a lead medical device reviewer and branch chief, worked on DARPA projects and consulted with CBER and CDER regarding regulatory submissions.

David holds a Master of Mechanical Engineering from Johns Hopkins University, a BSE in Biomedical Engineering from Case Western Reserve University, and a Certificate from HBX, now Harvard Business School Online.

Sevan Balian who is the Managing Partner of Balian Strategic Partners provides international institutional grade market entry intelligence and fiduciary-level readiness assessments for International medtech companies.

Through this partnership, Synera extends its physician led clinical, regulatory, and commercialization framework with board level market entry rigor, ensuring that US expansion decisions are grounded in clinical reality, regulatory certainty, and capital protection.

Sevan serves as a Strategic Partner to Synera, advising on US market entry strategy, board level decision frameworks, and international commercialization risk for medtech innovators.

Sevan's partnership strengthens this ecosystem by introducing a fiduciary grade decision lens, tailored specifically to European boards and founders navigating the structural, economic and cultural complexity of the US Healthcare system.

This alignment ensures that strategic amhbition is matched with execution reality.

Ashley Elsner serves as a strategic legal and operational partner to early and growth stage companies navigating fundraising, scaling, regulatory complexity and founder risk. As a two-time fintech founder and seasoned startup attorney, Ashley brings a rare-operator level perspective to legal strategy bridging law, business execution, and venture dynamics.

Through a strategic partnership with Synera Advisory, Ashley supports founders and leadership teams in building investor-ready, defensible, and scalable corporate foundations that align legal infrastructure with commercialization and growth strategy.

David Pennington is a seasoned MedTech and biologics executive with more than 20 years of experience leading commercialization, sales strategy, and global business growth across medical devices, human tissue / biologics, and healthcare SaaS. He brings a rare combination of clinical training, executive leadership, and P&L ownership, enabling companies, to successfully bridge the gap between clinical innovation and scalable commercial execution.

David has built and led high-performing sales and commercial organizations across opthamalogy, orthopedics, sports medicine,  uro-gynecology, cardiology, and regenerative medicine, consistently delivering measurable outcomes. His track record includes 150% year over year revenue growth, multimillion dollar strategic partnerships, full P&L responsibility, and five successful exits spanning venture-backed startups and growth stage enterprises.

Lucas is the Founder and Managing Director of Gradical, a Switzerland based consultancy specializing in sustainable, regulatory compliant plastics for medical technology.  Through Gradient's  proprietary Gradematch Framework, Lucas supports Medtech companies in reducing CO2 emissions without compromising device performance, regulatory compliance, or cost efficiency.

Lucas is widely recognized as a thought leader in sustainable materials strategy for medical devices, frequently contributing through speaking engagements, podcasts, and industry forums.

Rob Matzkin is a turnaround CEO, fractional CRO, and strategic operator with over 20 years of experience rebuilding and scaling mid market companies into high-performing acquisition ready organizations.

Rob specializes in stepping into companies at critical inflection points, whether stalled growth, operational misalignment, or pre-exit preparation while rapidly restoring clarity, structure, and execution across leadership, operations, and revenue functions.

As Founder of Rob Matzkin Group, Rob partners with founders, CEOs, and private equity-backed companies to rebuild core operating systems, optimize go to market strategy,, and drive sustainable market growth. His work spans AI, SaaS, healthcare, logistics,  consumer, and travel sectors with over $24 billion in business operations and transactions. 

At Synera, Rob serves as a strategic execution partner, supporting commercialization, revenue transformation, operational scale, and investor readineess across portfolio companies.

Hakeem Adebiyi is a global market strategist and MedTech commercialization leader specializing in helping medical device companies and healthcare innovators successfully expand into international markets.

As CEO of Hands Associates and creator of the Healthcare Export Accelerator Program. Hakeem has built a proven framework for guiding startups and SMEs through the complexities of global market entry, distribution strategy, and international scale. His work focuses on transforming early-stage and growth-stage companies into globally positioned, commercially viable organizations.

Hakeem brings deep expertise in export strategy, market access, and cross-border commercialization, supporting companies in navigating regulatory environments, identifying strategic partners, and executing scalable-go-to-market strategies across Europe, the UK, and emerging international markets.

His leadership experience includes serving as Chief Commercial Officer within MedTech, where he led global business development and expansion iniitatives, as well as advising organizations on strategic growth, sales acceleration, and international positioning.

At Synera Hakeem serves as a strategic partner for global commercialization, supporting international market entry, distribution strategy, and cross-border growth initiatives for medical device, digital health, and healthcare technology companies.

Kamal Lufti is a MedTech commercialization strategist specializing in market entry, distribution structuring, and execution across the Gulf Cooperation Council (GCC) and broader Middle East and Africa (MEA) markets.

With over 15 years of experience operating across regional healthcare systems, hospital environments, and distributor networks, Kamal brings a rate level of execution insight into how MedTech companies successfully enter and scale within MEA and why many fail.

As Founder of KLMedtech Innovation Advisory, Kamal partners with MedTech CEOs, founders, and commercial leaders to design and implement the correct market entry strategy before capital is deployed, distributors are selected, and commercialization pathways are locked in. His work focuses on eliminating structural risk early ensuring alignment across regulatory pathways, distributor selection, pricing, and timing.

Kamal is particularly focused on supporting FDA and CE cleared MedTech companies generating meaningful revenue in their home markets as they expand into GCC / MEA where misaligned strategies frequently  result in delayed traction, wasted capital, and failed market entry.

At Synera, Kamal serves as a strategic partner for GCC and MEA commercialization, supporting market entry, distribution strategy, and regional execution across medical device and healthcare technology portfolios.